Product: MCP1 Antibody
Catalog: DF7577
Description: Rabbit polyclonal antibody to MCP1
Application: WB IHC IF/ICC
Cited expt.: WB, IHC, IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Horse
Mol.Wt.: 14 kDa; 11kD(Calculated).
Uniprot: P13500
RRID: AB_2841069

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Horse(83%)
Clonality:
Polyclonal
Specificity:
MCP1 Antibody detects endogenous levels of total MCP1.
RRID:
AB_2841069
Cite Format: Affinity Biosciences Cat# DF7577, RRID:AB_2841069.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

C-C motif chemokine 2; CCL2; CCL2_HUMAN; Chemokine (C C motif) ligand 2; GDCF 2; GDCF-2; GDCF2; HC11; HSMCR30; JE; MCAF; MCP 1; MCP-1; MCP1; MGC9434; Monocyte chemoattractant protein 1; Monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; SCYA2; Small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig je); Small inducible cytokine A2; Small inducible cytokine subfamily A (Cys Cys), member 2; Small-inducible cytokine A2; SMC CF; SMC-CF; SMCCF;

Immunogens

Immunogen:

A synthesized peptide derived from human MCP1, corresponding to a region within the internal amino acids.

Uniprot:
Gene(ID):
Expression:
P13500 CCL2_HUMAN:

Expressed in the seminal plasma, endometrial fluid and follicular fluid (at protein level) (PubMed:23765988). Expressed in monocytes (PubMed:2513477).

Sequence:
MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
83
Pig
0
Bovine
0
Sheep
0
Dog
0
Xenopus
0
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Acts as a ligand for C-C chemokine receptor CCR2. Signals through binding and activation of CCR2 and induces a strong chemotactic response and mobilization of intracellular calcium ions. Exhibits a chemotactic activity for monocytes and basophils but not neutrophils or eosinophils. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis.

PTMs:

Processing at the N-terminus can regulate receptor and target cell selectivity. Deletion of the N-terminal residue converts it from an activator of basophil to an eosinophil chemoattractant.

N-Glycosylated.

Subcellular Location:

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in the seminal plasma, endometrial fluid and follicular fluid (at protein level). Expressed in monocytes.

Family&Domains:

Belongs to the intercrine beta (chemokine CC) family.

Research Fields

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

References

1). Gut Metabolite Indole-3-Propionic Acid Regulates Macrophage Autophagy Through PPT1 Inhibiting Aging-Related Myocardial Fibrosis. Advanced Science, 2025 [IF=14.1]

Application: IHC    Species: Mouse    Sample:

Figure 5 Transgenic knockout of macrophage PPT1 improves cardiac inflammatory infiltration and myocardial fibrosis in D-gal induce-aged mice. A) Schematic of the experimental design. B) Representative echocardiographic graphs. C–J) Echocardiographic measurements of LVEF, LVFS, LVIDd, LVIDs, LVPWd, LVPWs, IVSd, and IVSs. K) H&E staining of left ventricles. Magnification: 200×, scale bar = 50 µm. L) Masson's staining of left ventricles. Magnification: 200×, scale bar = 50 µm. M,N) Representative images of IHC staining with MCP-1 and α-SMA antibody. Magnification: 200×, scale bar = 50 µm. O) Statistical graphs of Masson's staining. P,Q) Statistical graphs of IHC staining with MCP-1 and α-SMA antibody. R) Representative images of the immunofluorescence of CD68, PPT1, and DAPI in mice heart. Magnification: 200×, scale bar = 20 µm. S) Statistical analysis of COL3A1, COL1A1, PPT1, IL-6, and TNF-α mRNA level. T,U) Representative images and statistical analysis of COL3A1, COL1A1, PPT1, IL-6, and TNF-α at protein level. (n = 5–6, data are expressed as mean ± SEM, **p < 0.01 vs the WT group; #p < 0.05, ##p < 0.01 vs the D-gal group).

2). Outer membrane vesicles derived from gut microbiota mediate tubulointerstitial inflammation: a potential new mechanism for diabetic kidney disease. Theranostics, 2023 (PubMed: 37554279) [IF=12.4]

Application: IHC    Species: Rat    Sample:

Figure 1 Gut microbiota depletion attenuates systemic and tubulointerstitial inflammation in diabetic rats. Gut microbiota of DM rats was depleted by treatment with broad-spectrum antibiotics administered in the drinking water (DM+AB). (A) Serum inflammatory cytokines, including IL-1β, TNF-α, MCP-1 and IL-6, were measured by ELISA (n=4). (B) Tubulointerstitial inflammation was detected by immunohistochemical staining (scale bar, 500 μm and 100 μm, original magnification × 200). (C-D) Expression levels of inflammatory proteins in renal cortex were detected by Western blot analysis and quantified (n=4-5). (E-F) Histopathological injuries of tubulointerstitium were evaluated by PAS staining (scale bar, 500 μm and 100 μm, original magnification × 200) and quantified (n=5).

Application: WB    Species: Rat    Sample:

Figure 1 Gut microbiota depletion attenuates systemic and tubulointerstitial inflammation in diabetic rats. Gut microbiota of DM rats was depleted by treatment with broad-spectrum antibiotics administered in the drinking water (DM+AB). (A) Serum inflammatory cytokines, including IL-1β, TNF-α, MCP-1 and IL-6, were measured by ELISA (n=4). (B) Tubulointerstitial inflammation was detected by immunohistochemical staining (scale bar, 500 μm and 100 μm, original magnification × 200). (C-D) Expression levels of inflammatory proteins in renal cortex were detected by Western blot analysis and quantified (n=4-5). (E-F) Histopathological injuries of tubulointerstitium were evaluated by PAS staining (scale bar, 500 μm and 100 μm, original magnification × 200) and quantified (n=5).

3). KIM-1 augments hypoxia-induced tubulointerstitial inflammation through uptake of small extracellular vesicles by tubular epithelial cells. Molecular therapy : the journal of the American Society of Gene Therapy, 2023 (PubMed: 35982620) [IF=12.1]

4). Ly6G+ Neutrophils and Interleukin-17 Are Essential in Protection against Rodent Malaria Caused by Plasmodium berghei ANKA. Research (Washington, D.C.), 2024 (PubMed: 39703777) [IF=11.0]

5). HIF-1α/JMJD1A signaling regulates inflammation and oxidative stress following hyperglycemia and hypoxia-induced vascular cell injury. CELLULAR & MOLECULAR BIOLOGY LETTERS, 2021 (PubMed: 34479471) [IF=9.2]

Application: WB    Species: human    Sample: HUVECs

Fig. 3 | Efects of inhibition of HIF-1α on expression of infammation after hyperglycemic and hypoxia.b Cells were treated with KC7F2 (10 µM) or si-HIF-1α for 48 h following combined stimulation, and IL-6, IL-8, ICAM-1, MCP-1, and c HIF-1α levels were analyzed. The relative density of IL-6, IL-8,ICAM-1, and MCP-1 (d) was normalized according to GAPDH expression.

Application: WB    Species: Human    Sample: HUVECs

Fig. 3 Effects of inhibition of HIF-1α on expression of inflammation after hyperglycemic and hypoxia. a Cells were treated with glucose (25 mM) or with combined exposure to high glucose and hypoxia for 6, 12, 24, and 48 h. Exposure to glucose alone or combined stimulation with hypoxia significantly increased gene expression of HIF-1α. b Cells were treated with KC7F2 (10 µM) or si-HIF-1α for 48 h following combined stimulation, and IL-6, IL-8, ICAM-1, MCP-1, and c HIF-1α levels were analyzed. The relative density of IL-6, IL-8, ICAM-1, and MCP-1 (d) was normalized according to GAPDH expression. Importantly, the downregulation of HIF-1α decreased the secretion of IL-6, IL-8, ICAM-1 and MCP-1 based on ELISA and qRT-PCR assays (e–f). n = 3; *p < 0.05 and **p < 0.01 vs. DMSO. DMSO-treated cells, DMSO; HIF-1α inhibitors KC7F2 (10 µM)-treated cells, KC7F2 (10 µM); si-HIF-1α, small interfering RNA HIF-1α; HG, high glucose; HG + Hypoxia, combined stimulus with high glucose and hypoxia; NG, control

6). Micheliolide Ameliorates Diabetic Kidney Disease by Inhibiting Mtdh-mediated Renal Inflammation in Type 2 Diabetic db/db Mice. PHARMACOLOGICAL RESEARCH, 2019 (PubMed: 31669149) [IF=9.1]

7). A bioactive xyloglucan polysaccharide hydrogel mechanically enhanced by Pluronic F127 micelles for promoting chronic wound healing. International journal of biological macromolecules, 2024 (PubMed: 39047998) [IF=7.7]

8). Pyrogallol enhances therapeutic effect of human umbilical cord mesenchymal stem cells against LPS-mediated inflammation and lung injury via activation of Nrf2/HO-1 signaling. Free radical biology & medicine, 2022 (PubMed: 36028178) [IF=7.1]

9). Interruption of TRPC6-NFATC1 signaling inhibits NADPH oxidase 4 and VSMCs phenotypic switch in intracranial aneurysm. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023 (PubMed: 37002575) [IF=6.9]

10). Oxoaporphine Pr(III) complex inhibits hepatocellular carcinoma progression and metastasis by disrupting tumor cell-macrophage crosstalk. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023 (PubMed: 37976890) [IF=6.9]

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.